Biotia Raises $9M for Infection Diagnostics

Biotia’s new funding shows continued investor interest in diagnostics that combine laboratory science with richer data analysis.

What happened

Biotia raised an oversubscribed $9 million financing round to scale its clinical metagenomics diagnostics business. Its BIOTIA-ID Urine Test is used for recurrent and complicated UTIs, and the company plans to expand into additional women’s health and orthopedic diagnostics.

The company also expanded its board as it prepares for broader commercial growth.

Why it matters

Some infections are difficult to diagnose with conventional lab methods, especially when patients have recurring symptoms or complex clinical histories. Metagenomics can help identify organisms through sequencing rather than relying only on narrower culture-based approaches.

If Biotia can make that workflow practical for more clinical settings, it could help doctors identify infections more accurately and select more appropriate treatments.

The bigger picture

Diagnostics is becoming more data-driven. Sequencing, software and clinical decision support are converging, especially in areas where standard tests leave uncertainty. Biotia’s raise is a smaller round, but it points to a wider shift toward more precise infectious-disease testing.